期刊文献+

〈50岁PSA4~1μg/L患者前列腺穿刺的临床病理特点分析 被引量:5

Ciinicopathologic analysis of prostate biopsy in men younger than 50 years of age with prostate-spe- cific antigen 4 - 10 μg/L
原文传递
导出
摘要 目的探讨〈50岁PSA4~10μg/L患者前列腺穿刺的临床病理特点。方法本组22例,年龄24~49岁,平均43岁。患者均无前列腺癌家族史。PSA值4.17—9.74μg/L,平均7.08μg/L。穿刺的原因为游离/总PSA≤0.16(20例)和(或)直肠指检阳性(4例)。本组游离/总PSA为0.03~0.53,平均0.11;前列腺体积13~74ml,平均39ml;PSA密度0.08—0.61,平均0.23。超声检查发现低回声改变或MRI检查发现低回声结节而可疑前列腺癌者13例。22例均行经直肠超声引导下经直肠前列腺穿刺活检术。结果22例中确诊为前列腺腺癌1例(4.5%),结核2例(9.1%),前列腺炎症9例(40.9%),未见异常10例(45.5%)。20例游离/总PSA≤0.16患者中,1例确诊为前列腺腺癌;4例直肠指检阳性患者中,2例诊断为结核,1例为炎症。结论〈50岁PSA4—10μg/L的年轻人中,前列腺穿刺主要的临床病理特点可能是前列腺增生以及前列腺组织内的炎症。 Objective To discuss the prostate biopsy results in young men with age less than 50 years and with PSA 4 - 10 μg/L. Methods From January 2006 to December 2011, 22 patients with PSA 4 -10 μg/L underwent prostate biopsy for free/total PSA ≤0.16 (20 cases) and/or positive digital rectal examination (DRE) (4 cases). The mean age was 43 years (range, 24 -49 years) , the mean PSA level was 7.08 μg/L (range, 4. 17 - 9.74 μg/L) , the mean free/total PSA level was 0. 11 (range, 0.03 - 0.53). Radiologic suspicious lesion was founded in 13 cases. Clinicopathological data from these patients were reviewed. Results The results of the biopsy were 1 (4.5%) case of prostate cancer, 2 cases (9.1%) with tuberculosis, 9 cases (40.9%) with inflammation, 10 cases (45.5%) with benign tissue. In 20 cases with free/total PSA≤0.16, only 1 case was diagnosed as prostate cancer. In 4 cases with posi- tive DRE, tuberculosis (2 cases) and inflammation (1 case) were diagnosed. Conclusions The prostate cancer detection was rare in young men less than 50 years of age with PSA 4 - 10 μg/L. The most common cause was prostate hyperplasia with inflammation.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2012年第11期840-842,共3页 Chinese Journal of Urology
关键词 前列腺特异抗原 直肠指检 活组织检查 针吸 前列腺肿瘤 Prostate-specific antigen Digital rectal examination Biopsy, needle Prostatic neoplasms
  • 相关文献

参考文献2

二级参考文献37

  • 1李鸣.前列腺癌诊断治疗指南.见:那彦群,孙光主编.中国泌尿外科疾病诊断治疗指南.北京:人民卫生出版社,2009,48-49.
  • 2Schroder FH.PSA screening:a review of recent studies.Eur J Cancer 2009; 45 Suppl Ⅰ:s402-s404.
  • 3Hoffman RM.Randomized trial results did not resolve controversies surrounding prostate cancer screening.Curt Opin Urol 2010; 20:189-193.
  • 4Shteynshlyuger A,Andriole GL.Prostate cancer:to screen or not to screen? Urol Clin North Am 2010; 37:1-9.
  • 5Catalona W J,Smith DS,Ornstein DK.Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination.Enhancement of specificity with free PSA measurements.JAMA 1997; 277:1452-1455.
  • 6Oesterling JE,Jacobsen SJ,Chute CG,Guess HA,Girman CJ,Panser LA,et al.Serum prostate-specific antigen in a community-based population of healthy men.Establishment of age-specific reference ranges.JAMA 1993; 270:860-864.
  • 7el-Galley RE,Petros JA,Sanders WH,Keane TE,Galloway NT,Cooner WH,et al.Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.Urology 1995; 46:200-204.
  • 8Morgan TO,Jacobsen S J,McCarthy WF,Jacobson DJ,McLeod DG,Moul JW.Age-specific reference ranges for prostate-specific antigen in black men.N Engl J Med 1996;335:304-310.
  • 9He D,Wang M,Chen X,Gao Z,He H,Zhau HE,et al.Ethnic differences in distribution of serum prostate-specific antigen:a study in a healthy Chinese male population.Urology 2004;63:722-726.
  • 10Oesterling JE,Kumamoto Y,Tsukamoto T,Girman CJ,Guess HA,Masumori N,et al.Serum prostate-specific antigen in a community-based population of healthy Japanese men:lower values than for similarly aged white men.Br J Urol 1995; 75:347-353.

共引文献15

同被引文献41

  • 1金保方,黄宇峰,杨晓玉,贾永华,邵常安,徐福松.1186例男性不育患者实验室检查结果及病因分析[J].南京中医药大学学报,2005,21(5):318-320. 被引量:25
  • 2谢军,刘继红,陈俊,马磊,邓荣进,王涛,王少刚,叶章群.精浆弹性硬蛋白酶、果糖和中性α-葡萄糖苷酶测定在梗阻性无精子症诊断中的意义[J].中国男科学杂志,2007,21(3):47-50. 被引量:30
  • 3王晓峰.男科疾病诊治进展[M].北京:人民军医出版社,2012:144.
  • 4世界卫生组织.WHO人类精液及精子-宫颈黏液相互作用实验检验手册[M].4版,北京:人民卫生出版社,2001.
  • 5Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)[EB/OL].[2012-8-20]. http://seer.cancer.gov/archive/csr/1975_2009_pops09/.
  • 6AndrioleGL,CrawfordED,GrubbRLet al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up[J]. J Natl Cancer Inst,2012,104(2): 125-132.
  • 7Schr?derFH,HugossonJ,RoobolMJ,et al. Screening and prostate-cancer mortality in a randomized European study[J].N Engl J Med,2009,360(13): 1320-1328.
  • 8Urological Society of Australia and New Zealand PSA Testing Policy 2009[EB/OL].[2013-04-09]. http://www.usanz.org.au/uploads/29168/ufiles/USANZ_2009_PSA Testing_Policy_Final1.pdf.
  • 9RuskaKM,PartinAW,EpsteinJI, et al. Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings[J]. Urology, 1999, 53(6):1179-1183.
  • 10YangJB,JeongBC,SeoSI, et al. Outcome of prostate biopsy in men younger than 40 years of age with high prostate-specific antigen(PSA) levels[J]. Korean I Urol, 2010, 51(1):21-24.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部